Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.) — Q1 2014 Form 10-Q Summary
Business context and reporting period
The filing covers the three months ended March 31, 2014. The company operated as a single drug discovery and development segment focused on antisense therapeutics, with 32 drugs in development and KYNAMRO marketed in the United States for homozygous familial hypercholesterolemia. The financial statements are unaudited.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $28.2 million | $43.4 million | Down 35% |
| Research and development collaboration revenue | $19.6 million | $41.7 million | Down 53% |
| Licensing and royalty revenue | $8.6 million | $1.7 million | Up 410% |
| Operating expenses | $57.8 million | $41.7 million | Up 39% |
| Loss from operations | $29.7 million | $1.6 million income | Material deterioration |
| Net loss | $31.3 million | $1.7 million | Material deterioration |
| Net loss per share | $0.27 | $0.02 | Higher loss |
| Net operating cash used | $32.3 million | $10.6 million | Higher cash use |
Approximate operating margin was negative 105% in Q1 2014 versus positive 4% in Q1 2013. Approximate net margin was negative 111% versus negative 4% in the prior-year period. Research, development and patent expense increased to $53.4 million from $38.3 million, primarily as the pipeline moved into later-stage and larger clinical trials. Stock-based compensation increased to $7.1 million from $2.9 million.
At March 31, 2014, cash and cash equivalents were $161.8 million, short-term investments were $469.5 million, and total liquidity was approximately $631.3 million, compared with $656.8 million at year-end 2013. Working capital was $621.2 million. Total assets were $834.6 million and stockholders’ equity was $374.1 million.
Carrying value of the 2.75% convertible senior notes was $152.0 million, with a stated fair value of $505.2 million. Debt and other obligations totaled approximately $282.5 million. Contractual obligations, including debt service, facility rent, leases and equipment financing, totaled approximately $405.3 million, including $330.3 million due after five years.
Material changes versus the prior comparable period
- Revenue declined primarily because Q1 2013 included a $25 million Genzyme milestone for KYNAMRO FDA approval and a $7.5 million GSK milestone related to ISIS-TTR Rx. Q1 2014 included $7.7 million of sublicensing revenue from Alnylam’s collaboration with Genzyme.
- Revenue became more concentrated among partners. Biogen Idec represented 36% of Q1 2014 revenue, Alnylam 27%, and GSK 12%. Two significant partners represented approximately 89% of contract receivables at March 31, 2014.
- Research and development spending increased as ISIS-TTR Rx advanced in Phase 3 and multiple other programs entered later-stage development. Manufacturing expense also increased to support clinical programs, including ISIS-APOCIII Rx.
- Cash declined by approximately $25.5 million from December 31, 2013 on a combined cash and short-term investment basis, despite more than $30 million received from partners and stock option exercises.
- The company amended its Biogen Idec collaboration for ISIS-SMN Rx, adding or expanding studies and increasing potential payments by nearly $35 million. The company received $9.3 million related to the amendment during Q1 2014 and was eligible for up to $303.8 million in total license fees and payments under the amended program.
- Regulus investment value increased to $63.6 million from $52.1 million at year-end, contributing to unrealized gains in other comprehensive income. Achaogen’s initial public offering caused the company’s investment to be reclassified to fair value.
Guidance, outlook, commentary and risks
Management did not provide clear full-year financial revenue or earnings guidance in the filing. Operational expectations included initiating a Phase 3 program for ISIS-APOCIII Rx in 2014, initiating a Phase 3 program for ISIS-SMN Rx around midyear 2014, and continuing Phase 3 development of ISIS-TTR Rx. Management stated that five pipeline drugs could be in registration or on the market by 2018, although this is a forward-looking expectation rather than a guarantee.
The company reported positive Phase 2 findings for ISIS-APOCIII Rx and positive clinical results for ISIS-SMN Rx in children and infants with spinal muscular atrophy. It also initiated Phase 1 studies for ISIS-HBV Rx and ISIS-ANGPTL3 Rx and added ISIS-HTT Rx to the pipeline.
Key risks include dependence on collaboration revenue and a relatively small number of partners; potential termination, delay or underfunding by Biogen Idec, Genzyme, GSK, Roche or other collaborators; clinical trial failure or delay; regulatory limitations and approval risk; uncertain commercial acceptance of KYNAMRO and future products; manufacturing and supply constraints; competition; intellectual-property disputes; and the need for additional financing if partnering or commercialization proceeds are insufficient.
KYNAMRO remains subject to a boxed warning for hepatic toxicity and a Risk Evaluation and Mitigation Strategy. Genzyme is responsible for commercialization and manufacturing of KYNAMRO, creating counterparty and execution risk. The company also disclosed ongoing patent litigation involving Santaris Pharma and Gilead Sciences.
The company used $32.3 million of cash in operations during the quarter and stated that it intended to use existing cash, cash equivalents and short-term investments to fund activities, while retaining the option to raise equity or debt financing. The filing text does not provide a clear estimate of when existing liquidity would be exhausted.
Important facts for investors to verify
- Whether collaboration and milestone revenue normalizes or remains volatile, particularly after the unusually large Q1 2013 milestones.
- Progress, enrollment, safety and efficacy results for the Phase 3 programs for ISIS-TTR Rx and planned ISIS-SMN Rx and ISIS-APOCIII Rx programs.
- KYNAMRO commercial sales, reimbursement, international approvals, safety monitoring and Genzyme’s ongoing commitment.
- The timing and probability of the next disclosed milestones, including the $18 million ISIS-SMN Rx milestone and additional GSK and Biogen Idec milestones.
- Quarterly operating cash burn relative to the approximately $631.3 million liquidity balance and the company’s $405.3 million of contractual obligations.
- Potential dilution or cash settlement associated with the convertible notes, which could convert into approximately 12.1 million shares under specified conditions.
- Developments and potential financial consequences of the Santaris and Gilead patent litigation.
- Valuation volatility and concentration risk associated with the $63.6 million Regulus investment and other biotechnology equity holdings.